Observed Signal · Jul 29, 2026 · earnings · Source: SEC API · Impact: 4.2/5
financials Market: 10-Q Financial Filing Analysis for CGI (2026-07-29)
Corcept Therapeutics reported strong financial results for the second quarter ended June 30, 2026, generating net product revenue of $256.1 million, a 31.7% increase year-over-year. Growth was accelerated by the commercial launch of Lifyorli (relacorilant) in combination with nab-paclitaxel for platinum-resistant ovarian cancer, which contributed $47.6 million in debut quarterly sales alongside core hypercortisolism therapies. On the regulatory and legal front, Corcept resubmitted its relacorilant NDA for endogenous Cushing's syndrome with a PDUFA date set for December 17, 2026, while the Court of Appeals affirmed a non-infringement ruling in the Teva patent litigation and denied a rehearing en banc in July 2026.
The filing highlights significant commercial diversification and top-line acceleration via the successful rollout of Lifyorli, alongside critical regulatory timelines for relacorilant and resolution of key patent litigation headwinds.
Key Takeaways & Evidence Grounding
- Q2 2026 net product revenue rose 31.7% year-over-year to $256.1 million, bolstered by $47.6 million in initial sales from newly launched Lifyorli.
- Corcept resubmitted its New Drug Application (NDA) for relacorilant in endogenous Cushing's syndrome on June 17, 2026, establishing an FDA PDUFA target action date of December 17, 2026.
- The Court of Appeals affirmed a District Court ruling of non-infringement in the Teva patent litigation, with a petition for rehearing en banc denied in July 2026.
Connected Companies & Entities
1 Entity mappedTrack Real-Time Market Signals & Shifts
Set up custom watchlists to receive automated, evidence-grounded executive digests whenever material signals or shifts occur across your tracked landscape.